Tags

Type your tag names separated by a space and hit enter

Atovaquone/proguanil for the prophylaxis and treatment of malaria.
Expert Rev Anti Infect Ther. 2005 Dec; 3(6):849-61.ER

Abstract

Increases in international travel and escalating drug resistance have resulted in a growing number of travelers at risk of contracting malaria. Drug resistance and intolerance to standard agents such as chloroquine, sulfadoxine/pyrimethamine and mefloquine has highlighted the need for new antimalarials. The recently licensed fixed combination of atovaquone and proguanil hydrochloride (Malarone) is a promising new agent to prevent and treat Plasmodium falciparum malaria. Randomized controlled trials have shown that atovaquone/proguanil is well tolerated and efficacious for the prevention and treatment of drug-resistant P. falciparum malaria. Atovaquone/proguanil is active against the liver stage of P. falciparum malaria parasites and when used as a prophylactic agent it can be discontinued shortly after leaving malaria-endemic areas, offering a clear advantage for drug adherence.

Authors+Show Affiliations

Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada. sn.patel@utoronto.caNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16307498

Citation

Patel, Samir N., and Kevin C. Kain. "Atovaquone/proguanil for the Prophylaxis and Treatment of Malaria." Expert Review of Anti-infective Therapy, vol. 3, no. 6, 2005, pp. 849-61.
Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther. 2005;3(6):849-61.
Patel, S. N., & Kain, K. C. (2005). Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Review of Anti-infective Therapy, 3(6), 849-61.
Patel SN, Kain KC. Atovaquone/proguanil for the Prophylaxis and Treatment of Malaria. Expert Rev Anti Infect Ther. 2005;3(6):849-61. PubMed PMID: 16307498.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atovaquone/proguanil for the prophylaxis and treatment of malaria. AU - Patel,Samir N, AU - Kain,Kevin C, PY - 2005/11/26/pubmed PY - 2006/7/25/medline PY - 2005/11/26/entrez SP - 849 EP - 61 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 3 IS - 6 N2 - Increases in international travel and escalating drug resistance have resulted in a growing number of travelers at risk of contracting malaria. Drug resistance and intolerance to standard agents such as chloroquine, sulfadoxine/pyrimethamine and mefloquine has highlighted the need for new antimalarials. The recently licensed fixed combination of atovaquone and proguanil hydrochloride (Malarone) is a promising new agent to prevent and treat Plasmodium falciparum malaria. Randomized controlled trials have shown that atovaquone/proguanil is well tolerated and efficacious for the prevention and treatment of drug-resistant P. falciparum malaria. Atovaquone/proguanil is active against the liver stage of P. falciparum malaria parasites and when used as a prophylactic agent it can be discontinued shortly after leaving malaria-endemic areas, offering a clear advantage for drug adherence. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/16307498/Atovaquone/proguanil_for_the_prophylaxis_and_treatment_of_malaria_ L2 - https://www.tandfonline.com/doi/full/10.1586/14787210.3.6.849 DB - PRIME DP - Unbound Medicine ER -